Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial update for CMOP±R in untreated Non-Hodgkin lymphoma; recruitment has not yet begun.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) [Phase 1]
Phase 1 study evaluating safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS research · 2024-06-17Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies [Phase 2]
This clinical trial update describes a Phase 2 study of anti-CD19 CAR-T cell therapy for B-cell hematologic malignancies, currently recruiti…
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating TAK-981 plus rituximab in adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma was terminated,…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial update examines using CD34+ malignant stem cell selection for patients receiving allogeneic stem cell transplants in Pha…
-
FDA approval · 2024-06-03FDA Approved: METHOTREXATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for methotrexate, authorizing the generic version of the drug.
-
CLINICAL_TRIALS research · 2024-05-23Clinical Trial Update: This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
This is a Phase II, open-label multicenter study evaluating regimens containing zanubrutinib in newly diagnosed mantle cell lymphoma. The tr…
-
CLINICAL_TRIALS research · 2024-05-23Clinical Trial Update: BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.
This clinical trial update discusses the implications of BCL6 rearrangements across non-Hodgkin lymphomas, including follicular lymphoma, ma…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 study update for CC-97540, a CD19-targeted NEX-T CAR T cell therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors [Phase 1]
A Phase 1 clinical trial of TR115 is currently recruiting in patients with relapsed/refractory non-Hodgkin's lymphoma and advanced solid tum…
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating CD19-BAFF CAR-T cells for relapsed or refractory B-cell acute lymphoblastic leukemia and B-cell n…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Heart Rate Variability, Vagus Nerve and Cancer [NA]
The trial investigating heart rate variability and vagus nerve stimulation in cancer has been terminated. The listed conditions across the s…
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 clinical trial evaluating rituximab in patients with newly diagnosed stage II, stage III, or stage IV follicular lymphoma has comple…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients [Phase 1]
A Phase I clinical trial update for ETH-155008 (Euthare-155008) in adult patients with non-Hodgkin lymphoma and recurrent acute myeloid leuk…
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) [Phase 2]
A Phase 2 clinical trial is evaluating entecavir prophylaxis to prevent hepatitis B reactivation in patients with resolved hepatitis B under…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) [Phase 2]
Phase 2 pediatric trial of Genistein for various cancers was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers [Phase 2]
A Phase 2 clinical trial update on haploidentical stem cell transplantation for multiple hematologic cancers, with the study status reported…
-
FDA approval · 2024-05-03FDA Approved: PLERIXAFOR — Original Application (Gland Pharma Limited)
FDA approved an original application for a generic version of plerixafor (ANDA206644) from Gland Pharma Limited for stem cell mobilization i…
-
CLINICAL_TRIALS research · 2024-05-02Clinical Trial Update: A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1]
This document reports an ongoing Phase 1 study evaluating CLN-978 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, current…
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research [EARLY_Phase 1]
A Phase 1 clinical trial update evaluating the safety and preliminary efficacy of metabolically armed CD19 CAR-T cells (Meta10-19) in relaps…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 trial evaluating ATG-019, a dual PAK4 and NAMPT inhibitor, in advanced solid tumors or Non-Hodgkin's lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) [Phase 2]
A pediatric MATCH phase 2 trial assessed olaparib in children with relapsed or refractory advanced solid tumors or non-Hodgkin lymphoma carr…
-
CLINICAL_TRIALS trial_result · 2024-04-24Clinical Trial Update: Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating palbociclib in relapsed or refractory pediatric tumors with activating alterations in cell cycle ge…
-
FDA approval · 2024-04-11FDA Approved: PLERIXAFOR — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for plerixafor (generic) under an ANDA. This action approves a change…